Berkeley, CA – According to filings with the U.S. Securities and Exchange Commission, Ansa Biotechnologies is raising $9,213,151.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Daniel Lin-Arlow played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ansa Biotechnologies

Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering. With synthetic DNA fueling innovation in biological research, therapeutics, diagnostics, and biomanufacturing, there is an urgent need for faster and more accurate DNA synthesis. Currently, DNA is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau.

To learn more about Ansa Biotechnologies, visit http://www.ansabio.com/

Contact:
Daniel Lin-Arlow, Chief Executive Officer
248-227-5556
https://www.linkedin.com/in/jeff-bertram-306654139/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved